423 related articles for article (PubMed ID: 32574517)
1. Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry.
Salisbury ML; Conoscenti CS; Culver DA; Yow E; Neely ML; Bender S; Hartmann N; Palmer SM; Leonard TB;
Ann Am Thorac Soc; 2020 Nov; 17(11):1413-1423. PubMed ID: 32574517
[No Abstract] [Full Text] [Related]
2. Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry.
Fan Y; Bender SD; Conoscenti CS; Davidson-Ray L; Cowper PA; Palmer SM; de Andrade JA;
Chest; 2020 Jun; 157(6):1522-1530. PubMed ID: 32004554
[TBL] [Abstract][Full Text] [Related]
3. Disease Severity and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis: A Cross-Sectional Analysis of the IPF-PRO Registry.
O'Brien EC; Hellkamp AS; Neely ML; Swaminathan A; Bender S; Snyder LD; Culver DA; Conoscenti CS; Todd JL; Palmer SM; Leonard TB;
Chest; 2020 May; 157(5):1188-1198. PubMed ID: 31954102
[TBL] [Abstract][Full Text] [Related]
4. Disparities in Lung Transplant among Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the IPF-PRO Registry.
Swaminathan AC; Hellkamp AS; Neely ML; Bender S; Paoletti L; White ES; Palmer SM; Whelan TPM; Dilling DF;
Ann Am Thorac Soc; 2022 Jun; 19(6):981-990. PubMed ID: 35073248
[No Abstract] [Full Text] [Related]
5. The impact of antifibrotic use on long-term clinical outcomes in the pulmonary fibrosis foundation registry.
Lee CT; Hao W; Burg CA; Best J; Kolenic GE; Strek ME
Respir Res; 2024 Jun; 25(1):255. PubMed ID: 38907239
[TBL] [Abstract][Full Text] [Related]
6. Hospitalizations in patients with idiopathic pulmonary fibrosis.
Kim HJ; Snyder LD; Adegunsoye A; Neely ML; Bender S; White ES; Conoscenti CS; Strek ME;
Respir Res; 2021 Sep; 22(1):257. PubMed ID: 34592998
[TBL] [Abstract][Full Text] [Related]
7. Associations between Patient-reported Outcomes and Death or Lung Transplant in Idiopathic Pulmonary Fibrosis. Data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry.
Case AH; Hellkamp AS; Neely ML; Bender S; Dilling DF; Gulati M; Hotchkin DL; Huie TJ; Lancaster L; Snyder LD; Conoscenti CS; Palmer SM
Ann Am Thorac Soc; 2020 Jun; 17(6):699-705. PubMed ID: 32040340
[No Abstract] [Full Text] [Related]
8. Lung function trajectories in patients with idiopathic pulmonary fibrosis.
Neely ML; Hellkamp AS; Bender S; Todd JL; Liesching T; Luckhardt TR; Oldham JM; Raj R; White ES; Palmer SM
Respir Res; 2023 Aug; 24(1):209. PubMed ID: 37612608
[TBL] [Abstract][Full Text] [Related]
9. Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry.
Snyder L; Neely ML; Hellkamp AS; O'Brien E; de Andrade J; Conoscenti CS; Leonard T; Bender S; Gulati M; Culver DA; Kaner RJ; Palmer S; Kim HJ;
Respir Res; 2019 May; 20(1):105. PubMed ID: 31142314
[TBL] [Abstract][Full Text] [Related]
10. Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry.
Holtze CH; Freiheit EA; Limb SL; Stauffer JL; Raimundo K; Pan WT; Flaherty KR; Kim HJ
Respir Res; 2020 Feb; 21(1):48. PubMed ID: 32041621
[TBL] [Abstract][Full Text] [Related]
11. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
Feng H; Zhao Y; Li Z; Kang J
Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
[TBL] [Abstract][Full Text] [Related]
12. Adoption of the Antifibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary Fibrosis.
Dempsey TM; Payne S; Sangaralingham L; Yao X; Shah ND; Limper AH
Ann Am Thorac Soc; 2021 Jul; 18(7):1121-1128. PubMed ID: 33465323
[No Abstract] [Full Text] [Related]
13. Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries.
Maher TM; Molina-Molina M; Russell AM; Bonella F; Jouneau S; Ripamonti E; Axmann J; Vancheri C
BMC Pulm Med; 2017 Sep; 17(1):124. PubMed ID: 28915874
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry.
Wuyts WA; Dahlqvist C; Slabbynck H; Schlesser M; Gusbin N; Compere C; Maddens S; Lee YC; Kirchgaessler KU; Bartley K; Bondue B
Respir Res; 2019 Oct; 20(1):231. PubMed ID: 31651324
[TBL] [Abstract][Full Text] [Related]
15. Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry.
Zurkova M; Kriegova E; Kolek V; Lostakova V; Sterclova M; Bartos V; Doubkova M; Binkova I; Svoboda M; Strenkova J; Janotova M; Plackova M; Lacina L; Rihak V; Petrik F; Lisa P; Bittenglova R; Tyl R; Ondrejka G; Suldova H; Lnenicka J; Psikalova J; Snizek T; Homolka J; Kralova R; Kervitzer J; Vasakova M; ;
Respir Res; 2019 Jan; 20(1):16. PubMed ID: 30665416
[TBL] [Abstract][Full Text] [Related]
16. Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry.
Kreuter M; Swigris J; Pittrow D; Geier S; Klotsche J; Prasse A; Wirtz H; Koschel D; Andreas S; Claussen M; Grohé C; Wilkens H; Hagmeyer L; Skowasch D; Meyer JF; Kirschner J; Gläser S; Herth FJF; Welte T; Neurohr C; Schwaiblmair M; Held M; Bahmer T; Frankenberger M; Behr J
Respir Res; 2017 Jul; 18(1):139. PubMed ID: 28709421
[TBL] [Abstract][Full Text] [Related]
17. Effect of Antifibrotic Therapy on Survival in Patients With Idiopathic Pulmonary Fibrosis.
de Andrade JA; Neely ML; Hellkamp AS; Culver DA; Kim HJ; Liesching T; Lobo LJ; Ramaswamy M; Safdar Z; Bender S; Conoscenti CS; Leonard TB; Palmer SM; Snyder LD;
Clin Ther; 2023 Apr; 45(4):306-315. PubMed ID: 36997445
[TBL] [Abstract][Full Text] [Related]
18. The effect of nintedanib on lung functions and survival in idiopathic pulmonary fibrosis: real-life analysis of the Czech EMPIRE registry.
Štefániková M; Doubková M; Ovesná P; Šterclová M; Lacina L; Žurková M; Plačková M; Bartoš V; Janíčková I; Bittenglová R; Anton J; Sýkorová Ľ; Lošťáková V; Musilová P; Šuldová H; Mokošová R; Didyk J; Šišáková L; Lisá P; Lněnička J; Dařičková H; Doležel D; Pšikalová J; Tyl R; Králová R; Vašáková MK
BMC Pulm Med; 2023 May; 23(1):154. PubMed ID: 37138274
[TBL] [Abstract][Full Text] [Related]
19. Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry.
Behr J; Prasse A; Wirtz H; Koschel D; Pittrow D; Held M; Klotsche J; Andreas S; Claussen M; Grohé C; Wilkens H; Hagmeyer L; Skowasch D; Meyer JF; Kirschner J; Gläser S; Kahn N; Welte T; Neurohr C; Schwaiblmair M; Bahmer T; Oqueka T; Frankenberger M; Kreuter M
Eur Respir J; 2020 Aug; 56(2):. PubMed ID: 32381492
[TBL] [Abstract][Full Text] [Related]
20. Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry.
de Andrade JA; Kulkarni T; Neely ML; Hellkamp AS; Case AH; Culver DA; Guntupalli K; Bender S; Conoscenti CS; Snyder LD;
Respir Res; 2022 Jan; 23(1):3. PubMed ID: 34996465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
